PluroGen Therapeutics, Inc.
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
| News Release |
FOR IMMEDIATE RELEASE Contact: Neal G. Koller
President & CEO
3 October 2007 Board of Directors
443 994 0101
PLUROGEN THERAPEUTICS INC. WINS THE VIRGINIA GROWTH COMPANIES TO
WATCH AWARD
(Charlottesville, VA, October 3, 2007) – PluroGen Therapeutics, Inc. today announced it won the
prestigious Virginia Growth Companies to Watch Award.
PluroGen was selected for this award by the Association for Corporate Growth (ACG) and The Venture
Forum. Neal G. Koller, President & CEO of PluroGen, received the award, which was presented by Patrick
O. Gottschalk, Secretary of Commerce and Trade for the Commonwealth of Virginia and Tom Roberts,
Partner, Harbert Venture Partners, during a special award ceremony held during the Virginia Capital Days
Conference in Richmond, VA.
Mr. Koller commented, “Winning this award is a terrific public recognition of the value PluroGen is providing
to the healthcare community and to the progress we have made as a company.”
About PluroGen Therapeutics, Inc.
Headquartered in Charlottesville, Va., PluroGen. is a biopharmaceutical company commercializing its patent-
protected technology platform of topical drug delivery materials, drug efficacy enhancement materials and
novel therapeutics into protected, advanced therapeutic products for simple and complex wound healing.
The product portfolio targets improved, protected therapies for the 6 Areas of Therapeutic Treatment (ATT)
of tissue healing (cleansing, infection, pain, inflammation, tissue salvage, tissue regeneration).
The company’s first two products, PluroGel Silver Sulfadiazine and TAG, are based on an advanced patent
protected topical drug delivery technology that has been successfully used in the U.Va. Medical Center on
more than 2,000 patients (approved through the UVA Medical Center’s internal pharmacy approval
process). PluroGen’s management and board of directors individually have more than 20 years of
experience working closely with the burn and wound care communities and the life science industry.
Statements included in this press release that are not historical in nature are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that
forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to
differ materially and which are identified from time to time in the Company’s reports filed with the U.S.
Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for
forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com
Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or
otherwise.
President & CEO
3 October 2007 Board of Directors
443 994 0101
PLUROGEN THERAPEUTICS INC. WINS THE VIRGINIA GROWTH COMPANIES TO
WATCH AWARD
(Charlottesville, VA, October 3, 2007) – PluroGen Therapeutics, Inc. today announced it won the
prestigious Virginia Growth Companies to Watch Award.
PluroGen was selected for this award by the Association for Corporate Growth (ACG) and The Venture
Forum. Neal G. Koller, President & CEO of PluroGen, received the award, which was presented by Patrick
O. Gottschalk, Secretary of Commerce and Trade for the Commonwealth of Virginia and Tom Roberts,
Partner, Harbert Venture Partners, during a special award ceremony held during the Virginia Capital Days
Conference in Richmond, VA.
Mr. Koller commented, “Winning this award is a terrific public recognition of the value PluroGen is providing
to the healthcare community and to the progress we have made as a company.”
About PluroGen Therapeutics, Inc.
Headquartered in Charlottesville, Va., PluroGen. is a biopharmaceutical company commercializing its patent-
protected technology platform of topical drug delivery materials, drug efficacy enhancement materials and
novel therapeutics into protected, advanced therapeutic products for simple and complex wound healing.
The product portfolio targets improved, protected therapies for the 6 Areas of Therapeutic Treatment (ATT)
of tissue healing (cleansing, infection, pain, inflammation, tissue salvage, tissue regeneration).
The company’s first two products, PluroGel Silver Sulfadiazine and TAG, are based on an advanced patent
protected topical drug delivery technology that has been successfully used in the U.Va. Medical Center on
more than 2,000 patients (approved through the UVA Medical Center’s internal pharmacy approval
process). PluroGen’s management and board of directors individually have more than 20 years of
experience working closely with the burn and wound care communities and the life science industry.
Statements included in this press release that are not historical in nature are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that
forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to
differ materially and which are identified from time to time in the Company’s reports filed with the U.S.
Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for
forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com
Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or
otherwise.